Using QPOP to Predict Treatment for Sarcomas and Melanomas

Recruiting now

Conditions studied: Sarcoma, Melanoma

In brief

This is a multi-cohort proof of concept study involving patients with sarcomas or melanomas. Patient models, both two- and three-dimensional, will be derived from tumour samples. These will then be used to evaluate drug sensitivities ex vivo. Enrolled patients will undergo resections or biopsies as part of standard-of-care, which will be used to generate patient models. Patients will receive standard-of-care systemic treatment. Patient models will also be subjected up to a 14-drug screening panel. The majority of drugs in the respective drug panels has been shown to have activity in the respective cancers and would be used in the standard-of-care setting by treating physicians.

Key facts

Study ID

NCT04986748

Run by

National Cancer Centre, Singapore

People needed

100

Starts

2020-09-08

Expected to finish

2028-12-31

Last updated by the study team

2025-07-01

Who can join

Age: 21 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of sarcoma or melanoma
• At least 1 tumour lesion amenable to fresh biopsy or resection
• Signed informed consent from patient or legal representative
• Able to comply with study-related procedures

You may not qualify if…

• There are no specific exclusion criteria if patients meet the inclusion criteria

Where it is running

• National Cancer Centre Singapore — Singapore, Singapore (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.